AIMS: To review the efficacy and safety of aprepitant in combination with ondansetron and dexamethasone (triple therapy) in children and adolescents on moderate to highly emetogenic chemotherapy. METHODS: Medline, Embase, Scielo, Lilacs, Cochrane and congress abstracts published until September 2016 were used as data sources. Two reviewers independently selected manuscripts and extracted data. A third reviewer solved discrepancies in study selection and data extraction. The primary outcome was overall complete response (no vomiting from 0 to 120 h). Secondary outcomes were: response in acute phase, delayed phase and reported toxicities. Each study was considered a unit of analysis. Summarized relative risks were recalculated based on reported data. All meta-analyses used a random-effects model and heterogeneity was reported using the I2 method. RESULTS: From 1004 studies, we screened 288 titles and abstracts and included three trials for data extraction. The population comprised 451 patients. Most patients were males, ranging from 6 months to 19 years of age, and weighing from 6 to 134 kg. Bone cancer was the most incident (≥50%) neoplasm, followed by rhabdomyosarcoma and Hodgkin's lymphoma. Triple therapy was associated with a reduced risk of developing chemotherapy-induced vomiting (CIV) (RR = 0.48; 95% CI 0.34-0.67). There were no differences in incidence of febrile neutropenia between groups (RR = 1.02; 95% CI 0.66-1.58). CONCLUSIONS: Triple therapy decreased CIV risk, without increasing the occurrence of febrile neutropenia. However, this review could not address which subpopulations would most benefit from using this strategy. Future studies should focus on assessing risk factors for nausea and vomiting, as many patients did not achieve a complete antiemetic response.
AIMS: To review the efficacy and safety of aprepitant in combination with ondansetron and dexamethasone (triple therapy) in children and adolescents on moderate to highly emetogenic chemotherapy. METHODS: Medline, Embase, Scielo, Lilacs, Cochrane and congress abstracts published until September 2016 were used as data sources. Two reviewers independently selected manuscripts and extracted data. A third reviewer solved discrepancies in study selection and data extraction. The primary outcome was overall complete response (no vomiting from 0 to 120 h). Secondary outcomes were: response in acute phase, delayed phase and reported toxicities. Each study was considered a unit of analysis. Summarized relative risks were recalculated based on reported data. All meta-analyses used a random-effects model and heterogeneity was reported using the I2 method. RESULTS: From 1004 studies, we screened 288 titles and abstracts and included three trials for data extraction. The population comprised 451 patients. Most patients were males, ranging from 6 months to 19 years of age, and weighing from 6 to 134 kg. Bone cancer was the most incident (≥50%) neoplasm, followed by rhabdomyosarcoma and Hodgkin's lymphoma. Triple therapy was associated with a reduced risk of developing chemotherapy-induced vomiting (CIV) (RR = 0.48; 95% CI 0.34-0.67). There were no differences in incidence of febrile neutropenia between groups (RR = 1.02; 95% CI 0.66-1.58). CONCLUSIONS: Triple therapy decreased CIV risk, without increasing the occurrence of febrile neutropenia. However, this review could not address which subpopulations would most benefit from using this strategy. Future studies should focus on assessing risk factors for nausea and vomiting, as many patients did not achieve a complete antiemetic response.
Authors: K Maie; Y Okoshi; N Takaiwa; N Kurita; Y Hasegawa; M Homma; K Ishii; Y Kohda; S Chiba Journal: Ann Oncol Date: 2013-11-26 Impact factor: 32.976
Authors: P J Hesketh; W H Harvey; W G Harker; T M Beck; T Ryan; L J Bricker; J A Kish; W K Murphy; J D Hainsworth; B Haley Journal: J Clin Oncol Date: 1994-03 Impact factor: 44.544
Authors: Paul J Hesketh; Kari Bohlke; Gary H Lyman; Ethan Basch; Maurice Chesney; Rebecca Anne Clark-Snow; Michael A Danso; Karin Jordan; Mark R Somerfield; Mark G Kris Journal: J Clin Oncol Date: 2015-11-02 Impact factor: 44.544
Authors: Maurice J D L van der Vorst; Elisabeth C W Neefjes; Inge R H M Konings; Henk M W Verheul Journal: Support Care Cancer Date: 2015-06-04 Impact factor: 3.603
Authors: Karin Melanie Cabanillas Stanchi; Martin Ebinger; Ulrike Hartmann; Manon Queudeville; Judith Feucht; Michael Ost; Marie-Sarah Koch; Carmen Malaval; Markus Mezger; Sarah Schober; Simone Weber; Sebastian Michaelis; Veit Lange; Peter Lang; Rupert Handgretinger; Michaela Döring Journal: Drug Des Devel Ther Date: 2019-09-30 Impact factor: 4.162